Perspective Therapeutics, Inc. CATX
0.87 USD +0.04 (+5.24%)
Nov 12, 2026, 10:58 AM EST
0.8252 Day range 0.8999
0.78 52-week range 6.16
- YTD
- -68.42%
- 1 year
- -59.04%
News
benzinga.com Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8 Truist Securities analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $11 to $8.
benzinga.com Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results Perspective Therapeutics Inc (NYSE:CATX) on Monday posted a narrower loss for the third quarter.
benzinga.com Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results Perspective Therapeutics narrowed its Q3 loss to $0.27/share, but sales fell. Analysts cut price targets, sending shares down 2.4%.
benzinga.com Wedbush Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $7 Wedbush analyst David Nierengarten maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $9 to $7.
benzinga.com Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $8 Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $14 to $8.
globenewswire.com Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results SEATTLE, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
globenewswire.com Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 SEATTLE, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
benzinga.com Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across…
globenewswire.com Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs SEATTLE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…- benzinga.com RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4 RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
benzinga.com Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced systemic treatments
benzinga.com Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle…- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
benzinga.com Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
benzinga.com Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
benzinga.com Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
benzinga.com This $3 Biotech Could Be Worth $11.45, Analyst Says William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
benzinga.com William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- benzinga.com BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11 BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
- benzinga.com B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5 B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
benzinga.com Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14 Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.- benzinga.com Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimate Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 26.67 percent increase over losses…
- benzinga.com Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gastroenteropancreatic Neuroendocrine Tumors The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).Orphan medicinal product designation by the EC may provide…
- benzinga.com Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
benzinga.com Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.
benzinga.com Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial to Meningioma Patients Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the…- benzinga.com Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharmaceutical Programs At ASCO 2026, Including 29% Response Rate In Advanced Melanoma Cohort One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily…
- benzinga.com Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/2a Studies In Neuroendocrine Tumors And Solid Tumors, Respectively The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin…
- benzinga.com Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is unchanged from the same period last…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer Trial, Says 43% Of Patients Show Tumor Response With New Radiotherapy Treatment Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced…
- benzinga.com HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $13 HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $12 to $13.
- benzinga.com B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $13 B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $11 to $13.
- benzinga.com UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8 UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $7 to $8.
- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026 Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced…
- benzinga.com RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $14 RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $18 to $14.
- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
- benzinga.com Perspective Therapeutics Q4 EPS $(0.51) Misses $(0.36) Estimate, Sales $43.000K Miss $215.615K Estimate. Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.36) by 42.06 percent. This is a 15 percent increase over losses…
- benzinga.com Earnings Scheduled For March 16, 2026
benzinga.com This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com Piper Sandler Initiates Coverage On Perspective Therapeutics with Overweight Rating, Announces Price Target of $16 Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Overweight rating and announces Price Target of $16.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $10 to $12.
- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.